Literature DB >> 16461211

The concept of hepatitis B virus mutant escape.

Jean-Michel Pawlotsky1.   

Abstract

Hepatitis B virus (HBV) reverse transcriptase is an error-prone enzyme, and this results in a large number of nucleotide substitutions during replication. As a result, HBV has a "quasispecies" distribution in infected individuals, meaning that HBV circulates as a complex mixture of genetically distinct but closely related variants that are in equilibrium at a given time point of infection in a given replicative environment. The quasispecies distribution of HBV implies that any newly generated mutation conferring a selective advantage to the virus in a given replicative environment will allow the corresponding viral population to overtake the other variants. Such selection processes occur at any step of infection to allow the emergence of variant viruses, such as precore and core promoter mutants during the natural course of infection, HBs antigen mutants under the pressure of active or passive anti-HBs immunization, or HBV mutants that are resistant to the antiviral action of specific HBV inhibitors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16461211     DOI: 10.1016/s1386-6532(05)80021-6

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  28 in total

Review 1.  Viral quasispecies evolution.

Authors:  Esteban Domingo; Julie Sheldon; Celia Perales
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

2.  Mutations in the S gene region of hepatitis B virus genotype D in Golestan Province-Iran.

Authors:  Abdolvahab Moradi; Sareh Zhand; Amir Ghaemi; Naeme Javid; Alijan Tabarraei
Journal:  Virus Genes       Date:  2012-01-25       Impact factor: 2.332

Review 3.  Pathogenesis of hepatitis B virus infection.

Authors:  Thomas F Baumert; Robert Thimme; Fritz von Weizsäcker
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

4.  Coexistence of hepatitis B virus quasispecies enhances viral replication and the ability to induce host antibody and cellular immune responses.

Authors:  Liang Cao; Chunchen Wu; Hui Shi; Zuojiong Gong; Ejuan Zhang; Hui Wang; Kaitao Zhao; Shuhui Liu; Songxia Li; Xiuzhu Gao; Yun Wang; Rongjuan Pei; Mengji Lu; Xinwen Chen
Journal:  J Virol       Date:  2014-05-21       Impact factor: 5.103

Review 5.  The underlying mechanisms for the "simultaneous HBsAg and anti-HBs serological profile".

Authors:  R A A Pondé
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-12       Impact factor: 3.267

6.  European multicenter evaluation of high-density DNA probe arrays for detection of hepatitis B virus resistance mutations and identification of genotypes.

Authors:  N Tran; R Berne; R Chann; M Gauthier; D Martin; M-A Armand; A Ollivet; C G Teo; S Ijaz; D Flichman; M Brunetto; K P Bielawski; C Pichoud; F Zoulim; G Vernet
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

Review 7.  Molecular biology of the hepatitis B virus for clinicians.

Authors:  Sibnarayan Datta; Soumya Chatterjee; Vijay Veer; Runu Chakravarty
Journal:  J Clin Exp Hepatol       Date:  2012-10-18

8.  Characterization of Full-Length Genomes of Hepatitis B Virus Quasispecies in Sera of Patients at Different Phases of Infection.

Authors:  Zhi-Tao Yang; Su-Yuan Huang; Li Chen; Feng Liu; Xiao-Hui Cai; Yang-Fan Guo; Ming-Jie Wang; Yue Han; De-Min Yu; Jie-Hong Jiang; Dong-Hua Zhang; Qi-Ming Gong; Guo-Qing Zhang; Guo-Qing Zang; Zhong-Hua Lu; Li-Hua Huang; Xin-Xin Zhang
Journal:  J Clin Microbiol       Date:  2015-04-29       Impact factor: 5.948

9.  Replication of clinical hepatitis B virus isolate and its application for selecting antiviral agents for chronic hepatitis B patients.

Authors:  Yin-Ping Lu; Tao Guo; Bao-Ju Wang; Ji-Hua Dong; Jian-Fang Zhu; Zhao Liu; Meng-Ji Lu; Dong-Liang Yang
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

Review 10.  Hepatitis B virus (HBV) reactivation-The potential role of direct-acting agents for hepatitis C virus (HCV).

Authors:  Jason T Blackard; Kenneth E Sherman
Journal:  Rev Med Virol       Date:  2018-05-15       Impact factor: 6.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.